Published in Respir Med on January 18, 2005
The role of measuring airway hyperresponsiveness and inflammatory biomarkers in asthma. Ther Clin Risk Manag (2005) 0.75
Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax (2012) 3.01
The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol (2013) 2.41
A probabilistic characterization of the relationship between fine particulate matter and mortality: elicitation of European experts. Environ Sci Technol (2007) 1.57
Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest (2005) 1.44
Quantifying the efficiency and equity implications of power plant air pollution control strategies in the United States. Environ Health Perspect (2007) 1.42
Estimation of primary and secondary particulate matter intake fractions for power plants in Georgia. Environ Sci Technol (2003) 1.42
High incidence of insulin resistance and dysglycemia amongst nondiabetic cardiac surgical patients. Ann Thorac Surg (2012) 1.41
Combined proximal endografting with distal bare-metal stenting for management of aortic dissection. Ann Thorac Surg (2011) 1.41
Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med (2004) 1.36
A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med (2006) 1.34
Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nephrol Dial Transplant (2005) 1.28
The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis (2008) 1.23
Intravenous leiomyomatosis with intracardiac extension - a review of diagnosis and management with an illustrative case. Surg Oncol (2013) 1.21
Barriers to pulmonary rehabilitation: characteristics that predict patient attendance and adherence. Respir Med (2012) 1.20
Long-acting beta2-agonists in asthma: not so SMART? Drug Saf (2006) 1.20
Factors influencing mobile source particulate matter emissions-to-exposure relationships in the Boston urban area. Environ Sci Technol (2007) 1.16
Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care (2005) 1.14
Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med (2002) 1.11
Enzyme-linked immunosorbent assay screening then indirect immunofluorescence confirmation of antinuclear antibodies: a statistical analysis. Am J Clin Pathol (2011) 1.05
Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol (2003) 1.02
A biomarker panel for peripheral arterial disease. Vasc Med (2008) 1.01
A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler (2010) 1.00
Biomarkers of peripheral arterial disease. J Am Coll Cardiol (2010) 0.98
Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study. Cardiovasc Diabetol (2011) 0.98
Improvement in timing and effectiveness of external cardiac compressions with a new non-invasive device: the CPR-Ezy. Resuscitation (2002) 0.94
The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax (2012) 0.93
Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. Thorax (2010) 0.91
Wolff-Parkinson-White syndrome mimicking acute inferolateral myocardial ischaemia in pneumonia. Resuscitation (2005) 0.90
Screening for IgG antinuclear autoantibodies by HEp-2 indirect fluorescent antibody assays and the need for standardization. Am J Clin Pathol (2012) 0.87
Vitamin D and COPD: seasonal variation is important. Thorax (2010) 0.86
Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest (2002) 0.86
A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. Br J Clin Pharmacol (2003) 0.86
Meta-review: adverse effects of inhaled corticosteroids relevant to older patients. Drugs (2014) 0.85
Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin. Med J Aust (2012) 0.84
Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 0.84
Myocardial production and release of MCP-1 and SDF-1 following myocardial infarction: differences between mice and man. J Transl Med (2011) 0.84
Determinants of airway hyperresponsiveness in mild asthma. Ann Allergy Asthma Immunol (2003) 0.83
Recent developments in asthma management. BMJ (2005) 0.83
Intermittent hypoxia conditioning prevents behavioral deficit and brain oxidative stress in ethanol-withdrawn rats. J Appl Physiol (1985) (2008) 0.81
Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol (2003) 0.81
Does diabetes mellitus alter the onset and clinical course of vascular dementia? Behav Neurol (2010) 0.81
Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children. Br J Clin Pharmacol (2002) 0.80
A nonfeminizing estrogen analog protects against ethanol withdrawal toxicity in immortalized hippocampal cells. J Pharmacol Exp Ther (2006) 0.80
Oral delivery of a probiotic induced changes at the nasal mucosa of seasonal allergic rhinitis subjects after local allergen challenge: a randomised clinical trial. PLoS One (2013) 0.80
When collateral supply is accounted for epicardial stenosis does not increase microvascular resistance. Circ Cardiovasc Interv (2012) 0.79
Ethanol withdrawal provokes opening of the mitochondrial membrane permeability transition pore in an estrogen-preventable manner. J Pharmacol Exp Ther (2008) 0.79
Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br J Clin Pharmacol (2004) 0.79
Impact of right atrial pressure on decision-making using fractional flow reserve (FFR) in elective percutaneous intervention. Int J Cardiol (2012) 0.78
Short-term repeatability and correlates of laboratory measures of nasal function in patients with seasonal allergic rhinitis. Rhinology (2002) 0.78
Managing chronic rhinosinusitis and respiratory disease: a qualitative study of triggers and interactions. J Asthma (2015) 0.78
5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol (2002) 0.78
Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Br J Clin Pharmacol (2007) 0.77
Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. Ann Allergy Asthma Immunol (2005) 0.77
Lower thresholds for bronchial challenge testing. Allergy (2004) 0.77
Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. Pharmacoeconomics (2014) 0.77
Uncertain biologic relevance of polymorphisms of leukotriene C4 synthase in asthma. J Allergy Clin Immunol (2005) 0.77
The effects of butterbur on the histamine and allergen cutaneous response. Ann Allergy Asthma Immunol (2004) 0.76
Effects of butterbur treatment in intermittent allergic rhinitis: a placebo-controlled evaluation. Ann Allergy Asthma Immunol (2004) 0.76
The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality. J Heart Valve Dis (2012) 0.76
Recurrent spontaneous coronary artery dissection with transient left ventricular systolic dysfunction. Int J Cardiol (2006) 0.76
Biomarkers in adult asthma: a systematic review of 8-isoprostane in exhaled breath condensate. J Breath Res (2017) 0.76
Intranasal and inhaled corticosteroids in allergic rhinitis and asthma. Br J Clin Pharmacol (2004) 0.75
The GOAL study: designed to favor a long-acting beta2-agonist? Am J Respir Crit Care Med (2005) 0.75
Lower airway physiological parameters in patients with allergic rhinitis. Respir Med (2005) 0.75
Recovery time following bronchial challenge. Respir Med (2004) 0.75
Modern histamine H1-receptor antagonists in the unified airway. J Allergy Clin Immunol (2004) 0.75
Nicotine and hypersensitivity pneumonitis. Am J Respir Crit Care Med (2004) 0.75
Addressing the long-term safety aspects of butterbur therapy: a call for immediate action. Arch Otolaryngol Head Neck Surg (2005) 0.75
ABC of chronic obstructive pulmonary disease. Pharmacological management--oral treatment. BMJ (2006) 0.75
Are colonial Haemophilus influenzae responsible for exacerbations of chronic obstructive pulmonary disease after all? Am J Respir Crit Care Med (2005) 0.75
Are vascular function measurements ready for the clinic? Eur Heart J (2005) 0.75
Nebulised salbutamol and magnesium sulphate in acute asthma. Lancet (2003) 0.75
Combined mediator blockade or topical corticosteroids for seasonal allergic rhinitis. J Allergy Clin Immunol (2002) 0.75
Asthma at-risk registers--can be effective if carefully constructed and correctly implemented. Prim Care Respir J (2012) 0.75
In vitro synergism of inhaled corticosteroid and long-acting beta2-agonist is not translated clinically in vivo. J Allergy Clin Immunol (2005) 0.75
Sputum eosinophils and bronchodilator reversibility: COPD or asthma? Chest (2005) 0.75
Beneficial antiinflammatory effects of leukotriene receptor antagonists in asthma. Chest (2005) 0.75
Decongestant effects of antihistamines: a class effect? J Allergy Clin Immunol (2003) 0.75
H1-antihistamines. N Engl J Med (2005) 0.75
Omalizumab and changes in airway hyperresponsiveness. Am J Respir Crit Care Med (2005) 0.75
Airway hyperresponsiveness and beta2-adrenoceptor genotypes and diplotypes at positions 16 and 27. Chest (2005) 0.75
beta(2)-Adrenergic receptor polymorphism in asthma: prospective versus retrospective perspective. J Allergy Clin Immunol (2005) 0.75
What about add-on second-line controller therapy? Chest (2005) 0.75
Effects of montelukast in patients with persistent asthma using inhaled corticosteroids plus additional second-line therapy. J Allergy Clin Immunol (2005) 0.75
Pulmonary rehabilitation and readmissions in COPD: hospital readmissions did not fall. BMJ (2005) 0.75
Intranasal corticosteroid therapy and bronchial hyperresponsiveness in the unified airway. Ann Allergy Asthma Immunol (2004) 0.75
Asthma exacerbations and inhaled corticosteroids. Lancet (2004) 0.75
Histamine and indirect bronchoprovocation with adenosine monophosphate in asthma. Respir Med (2005) 0.75
Author's response: co-trimoxazole treatment in idiopathic pulmonary fibrosis. Thorax (2013) 0.75
Combination therapy with a long-acting beta2-agonist and an inhaled corticosteroid as initial maintenance treatment in asthma. Ann Allergy Asthma Immunol (2005) 0.75
Exhaled nitric oxide and asthma. N Engl J Med (2005) 0.75
Treatment of mild asthma. N Engl J Med (2005) 0.75
Evaluating the effects of "triple therapy" with inhaled corticosteroids, long-acting beta2-agonists, and leukotriene modifiers in asthma. Chest (2006) 0.75
Asthma exacerbations and sputum eosinophil counts. Lancet (2003) 0.75
Airway hyperresponsiveness to bronchial mannitol: where do we go from here? Chest (2004) 0.75
Latent plaque rupture in a patient undergoing stenting for acute coronary syndrome and diffuse coronary disease: a case report and review of literature. Catheter Cardiovasc Interv (2006) 0.75
Alteplase beyond three hours in ischemic stroke: do we know enough? Int J Stroke (2009) 0.75
Thioflavin T fluorescence in human serum: correlations with vascular health and cardiovascular risk factors. Clin Biochem (2009) 0.75
Antibiotic resistance and nosocomial pneumonia. Respir Med (2005) 0.75
COPD: what is the diagnosis? Respir Med (2005) 0.75